Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease
This is a controlled investigation, with randomization of the patients, which aims at demonstrating the efficacy of device RGn600 in treating patients with mild-to-moderate Alzheimer's disease (AD). RGn600 is a non-invasive medical device which is applied on the head (helmet) and on the abdomen (abdominal belt). It com
| Condition(s) | Alzheimer Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This is a controlled investigation, with randomization of the patients, which aims at demonstrating the efficacy of device RGn600 in treating patients with mild-to-moderate Alzheimer's disease (AD). RGn600 is a non-invasive medical device which is applied on the head (helmet) and on the abdomen (abdominal belt). It combines 2 technologies: * PhotoBioModulation (PBM), which involves exposure to light from the red to near-infrared wavelengths using lasers and Light Emitting Diodes (LEDs) * Static Magnetic Stimulation (SMS), which consists in the application of a static magnetic field. Considering previous investigations, this innovative technology could reduce inflammation on the brain-gut axis, implicated in the development of Alzheimer's disease. |
| Who can participate | Inclusion Criteria: * Male or female aged 55 to 85 years old (both included) * Diagnosed with AD according to McKhann et al. international criteria dated 2011 * With mild-to-moderate AD, i.e., 10 ≤ MMSE score ≤ 26 * With blood analyses results (for: thyroid-stimulating hormone, vitamin B12, folate, complete blood count including platelets, electrolytes including calcium, creatinine, clearance, alanine aminotransferase, aspartate aminotransferase, bilirubin, coagulation, C-reactive protein) dated less than 1 year ago in line with AD diagnosis, as deemed by the investigator * With brain Computed Tomography (CT) or/and Magnetic Resonance Imaging (MRI) scan dated less than 1 year ago in line with AD diagnosis, as deemed by the investigator * In case of treatment with AD symptomatic treatments |
| Ages | 55 Years to 85 Years |
| Sex | All |
| Lead sponsor | REGEnLIFE SAS |
| Locations | Castres, France; Lavaur, France; Paris, France; Paris, France; Timone, France; Toulouse, France |
| Start date | 2023-07-24 |
| NCT ID | NCT05926011 |
| Official listing | https://clinicaltrials.gov/study/NCT05926011 |